

IP strategies for the biosimilar arena

Ulrich Storz

Michalski Huettermann Patent Attorneys, Germany

The patent term of some of the most important biopharmaceutical blockbusters is about to expire in the near future. While originators strive to extend the effective protection term for their major assets, biosimilar manufacturers prepare for market entry of their follow-on products.

The situation of biosimilars is in part comparable with that of small molecule generics, although significant differences apply, caused, among others, by post-translational differences biosimilars have compared to the respective archetype drug

This oral presentation will discuss active and passive IP strategies for both originators and biosimilar manufacturers.

Biography

Ulrich Storz was born in 1969 in Muenster. He graduated in Biology at the University of Muenster in 1998, where he received his PhD in 2002. He is author and co-author of several scientific publications in the field of biology and biophysics as well as of several publications in the field of intellectual property. He passed the German Patent Bar Examination in 2005. Since 2005, he has been admitted to practice as European Trademark Attorney at the European Trademark Office (OHIM). In 2006, he has been registered in the list of representatives before the European Patent Office. Main practice areas in the field of Intellectual Property Law include Patent Prosecution, FTO and Patent Infringement, as well as Patent strategies; especially in the Life Science field (i.e. Biotechnology, Biophysics, Biochemistry and Microbiology). One of his preferred fields of expertise are therapeutical antibodies. Ulrich Storz is active as a speaker for the congress management company "Forum Institut für Management GmbH". He organizes the "Rhineland Biopatent Forum", which takes place annually in May or June, and he is the editor of the textbook series "SpringerBriefs in Biotech Patents." Further, Ulrich has a lectureship at the University of Applied Sciences in Gelsenkirchen, Germany.

st@mhpatent.de